Context Therapeutics' (CNTX) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a research note released on Friday,Benzinga reports. They currently have a $9.00 price target on the stock.

Other research analysts have also issued research reports about the company. Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. JMP Securities began coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Friday. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Context Therapeutics presently has an average rating of "Buy" and a consensus price target of $6.17.

Context Therapeutics Trading Down 1.4 %

CNTX traded down $0.01 during midday trading on Friday, hitting $0.76. 33,761 shares of the company traded hands, compared to its average volume of 388,443. The company has a market capitalization of $57.06 million, a price-to-earnings ratio of -0.84 and a beta of 2.06. The business has a 50 day simple moving average of $0.85 and a two-hundred day simple moving average of $1.43. Context Therapeutics has a 52-week low of $0.64 and a 52-week high of $2.75.

Remove Ads

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. Equities research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds have recently modified their holdings of the company. MPM Bioimpact LLC purchased a new position in Context Therapeutics during the fourth quarter worth about $15,441,000. Franklin Resources Inc. increased its holdings in shares of Context Therapeutics by 115.9% during the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company's stock worth $4,204,000 after buying an additional 2,149,392 shares during the last quarter. Allostery Investments LP purchased a new stake in shares of Context Therapeutics during the 4th quarter valued at approximately $998,000. Blue Owl Capital Holdings LP lifted its holdings in Context Therapeutics by 17.5% in the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock valued at $6,676,000 after acquiring an additional 946,638 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Context Therapeutics by 412.8% in the fourth quarter. Renaissance Technologies LLC now owns 338,435 shares of the company's stock worth $355,000 after acquiring an additional 272,435 shares during the period. Hedge funds and other institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.